Blood test tells fetal sex in early pregnancy
Normally, parents who want to know the sex of their baby before it’s born find out through ultrasound done in the second trimester. A blood test that can be done early in pregnancy is highly accurate at determining the sex of the fetus, however, a new study finds.
The test is important, write the authors of the study, because in some cases, there are medical reasons to determine fetal sex earlier. That has traditionally meant invasive tests, like amniocentesis, which carry a small risk of miscarriage.
Consequently, maternal blood tests that pick up certain markers of fetal sex have been developed and put into use in recent years. So far, research has shown the accuracy of these tests to vary widely, depending on the methods used.
In this latest study, published in the journal Obstetrics & Gynecology, researchers in the Netherlands found that the testing method used at their center was 100 percent accurate in determining fetal sex among nearly 200 pregnant women.
Part of what’s new about the findings is that they show the effectiveness of blood testing as it is done in routine practice - and not just in the research setting, Dr. Ellen van der Schoot, of Sanquin Research Amsterdam, told Reuters Health in an email. The study does not discuss costs, nor when the test might be available to the general public.
Still, the findings, according to van der Schoot and her colleagues, support using the tests in cases where fetal sex is important in detecting or managing certain inherited medical conditions.
For example, congenital adrenal hyperplasia (CAH) is a genetic disorder that causes girls to develop abnormal external genitalia and male-like characteristics like a deep voice and excessive body hair.
It is possible, however, to treat the disorder with the steroid dexamethasone as soon as pregnancy is established, so knowing the fetal sex sooner is better than later.
Similarly, fetal sex is key in genetic disorders linked to abnormalities in the X chromosome. These disorders - such as hemophilia and Duchenne/Becker muscular dystrophy - are almost always seen in boys rather than girls, because boys inherit only one X chromosome, from the mother. (Girls inherit an X chromosome from each parent.)
In cases where a mother is known to carry an X-linked genetic defect, blood testing for fetal sex tells doctors whether further, invasive testing for the particular genetic disorder should be done. If the fetus is female, invasive tests can be avoided.
In the current study, van der Schoot and her colleagues looked at 201 pregnant women who had blood testing at their lab between 2003 and 2009. The test, done as early as the seventh week of pregnancy, determines fetal sex by looking for two genes found on the Y sex chromosome.
Only men carry the Y chromosome, so when these genes were found in a pregnant woman’s blood sample, the fetus was assumed to be male. When the test did not detect the genes, the mother’s blood was analyzed further to confirm that certain other fetal DNA was present; with that confirmation, the researchers concluded that the fetus was female.
Of the 201 women in this study, blood tests gave conclusive results to 189. In each case, that result turned out to be correct.
The test results also made a significant difference in how the pregnancies were managed from then on, according to van der Schoot and her colleagues. Among the 156 women who underwent testing because of the risk of an X-linked disorder, the results allowed 41 percent to avoid further, invasive procedures to test for the disorder.
In addition, 27 women who’d been taking steroids for possible CAH were able to stop, as the fetus was found to be male.
According to the researchers, the reliability of the blood tests means that invasive procedures are no longer necessary for determining fetal sex early in pregnancy.
Since the introduction of such blood testing, there have been ethical concerns about couples seeking testing solely to find out the sex of the fetus early on - and possibly ending the pregnancy based on that information.
“These concerns are relevant,” van der Schoot said, “and we agree that the test should be applied carefully in a clinical setting upon medical indication.”
SOURCE: Obstetrics & Gynecology, January 2010.
|Comments||[ + Post Your Own ]|
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.